Abstract
Background and Aims:
Automated insulin delivery (AID) systems achieve consistent glycemic outcomes in real-world settings, yet access across Latin America (LATAM) remains critically low, with marked disparities driven by demographic, structural, and health care infrastructure heterogeneity across the region. This study characterizes the real-world performance of the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system across 18 LATAM countries and evaluates the durability of glycemic outcomes over 24 months.
Methods:
Data from 16,669 individuals with type 1 diabetes using the MM780G system across 18 LATAM countries (January 2020–October 2025) were analyzed; 27.1% were pediatric (
Results:
Overall, mean TIR was 73.4% and GMI 6.9%, with TBR within consensus targets; approximately two-thirds of users achieved TIR > 70% and GMI 70% attainment occurred in 83.9% of users, and composite target of GMI 70, TB70
Conclusion:
The MiniMed™ 780G AHCL system delivered consistent and durable glycemic control over 24 months across the full demographic and structural heterogeneity of Latin America. Performance was aligned with internationally recommended consensus targets and was independent of age, sex, country, and health care infrastructure. Eliminating barriers to AID access is an immediate and achievable priority in the region and may improve the health of hundreds of thousands of people with diabetes in Latin America.